BMY · Bristol Myers Squibb & Co.
AI read · Good for BMY
The AI's read
These results give Bristol Myers Squibb 2 possible treatments that could move closer to patients. RYZ101 met its main trial goal, and the 60 mg admilparant dose improved lung capacity compared with a placebo. The 120 mg dose slowed the decline but did not show a clear enough result. RYZ101 also needs talks with regulators before a formal application. The 2 successful results outweigh these limits.